Skip to main content
main-content

Aflibercept

News

07-04-2017 | Diabetic complications | News

June Cochrane review round-up

Here we provide an overview of the seven Cochrane reviews published in June that covered topics relating to diabetes, including glycemic control for prevention of renal failure, phototherapy for foot ulcers, and anti-vascular endothelial growth factor treatment for diabetic macular edema.

05-12-2017 | Aflibercept | News

Aflibercept has edge over laser retinopathy treatment in CLARITY trial

Results of the CLARITY trial suggest that aflibercept treatment may produce better visual outcomes than laser photocoagulation in patients with proliferative diabetic retinopathy.

05-09-2017 | Aflibercept | News

Anti-VEGF therapy can improve diabetic retinopathy

A substantial proportion of diabetes patients experience improvements in diabetic retinopathy while receiving anti-vascular endothelial growth factor treatment, shows the latest analysis from DRCR.net.

Read more

Related topics

Superior

Related

Opinion

08-22-2017 | Retinopathy | Editorial | Article

Antivascular endothelial growth factor treatment for proliferative diabetic retinopathy: Perspective on the CLARITY study

In this editorial, Rishi Singh and colleagues provide their perspective on the future of proliferative diabetic retinopathy treatment following the completion of the CLARITY and Protocol S studies.

Journal articles and book chapters

10-01-2016 | Retinopathy | Review | Article

Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy

The beneficial effects of anti-VEGF agents on DR and the potential of arresting or in some cases improving DR severity are exciting and provocative. However, the durability of the effect of anti-VEGFs agents remains a significant limitation.

Dhoot DS & Avery RL. Curr Diab Rep 2016; 16: 122. doi:10.1007/s11892-016-0825-4

06-13-2014 | Diabetic complications | Review | Article

Anti-VEGF Therapy for Diabetic Macular Edema

Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of diabetic macular edema (DME). This review looks at a decade of evidence from clinical trials demonstrating that drugs that bind soluble VEGF (pegaptanib, ranibizumab, bevacizumab, and aflibercept) restore the integrity of the blood-retinal barrier, resolve macular edema, and improve vision in most patients with DME.

Stewart MW. Curr Diab Rep 2014;14:510. doi:10.1007/s11892-014-0510-4

image credits